Symphoricarpus Racemosus

Symphoricarpos Albus Fruit is a non-standardized plant allergenic extract used primarily for the diagnosis and treatment of IgE-mediated allergic sensitization to the common snowberry plant.

Dosage for Symphoricarpos Albus Fruit extract is highly individualized and must be determined by an allergist or immunologist based on the patient's sensitivity levels. There is no standard 'one-size-fits-all' dose.

Diagnostic Dosing

• Skin Prick Test (SPT): Typically, a drop of the 1:10 or 1:20 w/v concentrate is applied to the skin, followed by a puncture. A positive control (histamine) and negative control (saline) are used simultaneously.
• Intradermal Test: If SPT is negative, an intradermal injection of 0.02 mL to 0.05 mL of a highly diluted extract (e.g., 1:1000 or 1:500 w/v) may be administered.

Immunotherapy Dosing

• Build-up Phase: Treatment usually begins with a very low dose (e.g., 0.05 mL of a 1:100,000 w/v dilution). Doses are increased weekly or bi-weekly by 50% to 100% until the maintenance dose is reached.
• Maintenance Phase: Once the maximum tolerated dose is achieved (often 0.5 mL of a 1:10 or 1:20 w/v concentrate), the interval between injections is increased to every 2 to 4 weeks.

Symphoricarpos Albus Fruit extract may be used in children, but extreme caution is required. Dosing is generally based on the same principles as adult dosing—starting with very low concentrations and escalating based on local and systemic tolerance. Children under the age of 5 may be at higher risk for systemic reactions and may have difficulty communicating early symptoms of anaphylaxis. Pediatric use must be supervised by a specialist.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the extract is not cleared through the kidneys in a manner that affects its immunological activity.

Hepatic Impairment

No dosage adjustments are necessary for patients with hepatic impairment.

Elderly Patients

Elderly patients may have a reduced skin response to testing. Furthermore, the risk-benefit ratio must be carefully weighed in older adults with underlying cardiovascular disease, as they may be less able to tolerate the physiological stress of a systemic allergic reaction or the administration of epinephrine.

Symphoricarpos Albus Fruit extract is never for self-administration. It must be administered in a clinical setting by a healthcare professional.

1. 1Preparation: The skin (usually the forearm or back) is cleaned with alcohol.
2. 2Administration: For immunotherapy, the injection is given subcutaneously (under the skin), usually in the outer aspect of the upper arm. The site should be rotated between injections.
3. 3Observation: Patients must remain in the medical office for at least 30 minutes following any injection. This is the period of highest risk for life-threatening anaphylaxis.
4. 4Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

If a dose of immunotherapy is missed, the next dose may need to be reduced depending on how much time has elapsed. If the interval exceeds the recommended schedule by more than a week, the healthcare provider will typically drop back to a previous lower dose level to ensure safety and avoid a systemic reaction.

An 'overdose' in the context of allergenic extracts refers to the administration of a dose that exceeds the patient's current tolerance level. This can lead to severe systemic reactions or anaphylaxis.

• Signs of Overdose: Rapid onset of hives, swelling of the throat, wheezing, drop in blood pressure, or abdominal cramping.
• Emergency Measures: Immediate administration of epinephrine (1:1000), oxygen, intravenous fluids, and antihistamines. Emergency medical services must be contacted immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip appointments without medical guidance.

Most patients receiving Symphoricarpos Albus Fruit extract will experience some form of localized reaction. These are generally not dangerous but indicate the immune system is responding to the allergen.

• Local Wheal and Flare: A small, itchy bump at the injection site that appears within minutes and usually resolves within an hour.
• Late-Phase Local Reaction: Swelling, redness, and warmth at the injection site that develops 4 to 8 hours after administration. This can feel like a firm, sore lump and may last for 24 to 48 hours.
• Itching (Pruritus): General itching at the site of the skin test or injection.

Symphoricarpos Albus Fruit extract is a potent biological substance. Its use is restricted to diagnostic and therapeutic protocols managed by specialists. Patients must be aware that even if they have tolerated previous injections, a systemic reaction can occur at any time during the course of therapy.

No FDA black box warnings specifically for 'Symphoricarpos Albus Fruit' are currently listed, but it falls under the general safety mandates for all non-standardized allergenic extracts. The primary warning emphasizes that anaphylaxis is a constant risk and that the product is contraindicated in patients with severe, unstable, or steroid-dependent asthma.

• Anaphylaxis Risk: This is the most significant risk. Anaphylaxis can occur within seconds or minutes. Risk factors include high sensitivity levels, rapid dose escalation, and administration during peak allergy season.

• Beta-Blockers (e.g., Propranolol, Atenolol, Metoprolol): These medications are generally contraindicated in patients receiving allergenic extracts. Beta-blockers can make a systemic allergic reaction much more severe and, more importantly, they can block the effects of epinephrine, which is the primary treatment for anaphylaxis. This creates a situation where a reaction becomes 'refractory' (unresponsive) to treatment.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): These drugs may increase the risk of severe systemic reactions or worsen the hypotension (low blood pressure) associated with anaphylaxis.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of epinephrine, leading to a dangerous spike in blood pressure if epinephrine is needed to treat a reaction.

Symphoricarpos Albus Fruit must NEVER be used in the following circumstances:

1. 1Severe or Unstable Asthma: Patients with a Forced Expiratory Volume (FEV1) consistently below 70% of predicted or those with recent acute exacerbations are at an unacceptably high risk for fatal anaphylaxis.
2. 2Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The cardiovascular stress of a potential systemic reaction or the use of epinephrine could be fatal.
3. 3Hypersensitivity to Excipients: Patients with a known severe allergy to phenol (used as a preservative) or glycerin (used as a stabilizer) in the extract.
4. 4

Pregnancy Category C: There are no adequate and well-controlled studies of Symphoricarpos Albus Fruit extract in pregnant women. The primary concern is not teratogenicity (birth defects) from the extract itself, but the danger of maternal anaphylaxis. Anaphylaxis can lead to maternal hypotension, uterine contractions, and fetal hypoxia. It is generally recommended that immunotherapy NOT be initiated during pregnancy. If a woman becomes pregnant while on a stable maintenance dose, the physician may choose to continue the therapy but will usually not increase the dose until after delivery.

It is not known whether the components of Symphoricarpos Albus Fruit extract are excreted in human milk. Because the extract consists of proteins that are likely digested in the infant's gastrointestinal tract, the risk to a nursing infant is considered very low. Breastfeeding is generally not a contraindication for receiving allergy shots.

Allergen immunotherapy is generally considered safe for children age 5 and older. The efficacy in younger children is less well-documented, and the risks of systemic reactions are harder to manage. Pediatric patients must be monitored closely for 'behavioral' signs of an allergic reaction, such as sudden irritability or lethargy, as they may not be able to describe 'throat tightness.'

Symphoricarpos Albus Fruit extract functions as an immunomodulator. In sensitized individuals, the 'major allergens' (specific proteins) in the fruit bind to IgE antibodies on mast cells and basophils. This triggers a Type I hypersensitivity reaction. During therapeutic desensitization, the repeated administration of these proteins leads to:

1. 1Induction of T-regulatory (Treg) cells: These cells produce IL-10 and TGF-beta, which suppress the allergic Th2 response.
2. 2B-cell Class Switching: B-cells switch from producing IgE to producing IgG4. IgG4 acts as a 'blocking antibody,' preventing the allergen from reaching the IgE on mast cells.
3. 3Reduced Mast Cell Sensitivity: Over time, the threshold for mast cell degranulation is increased.